News | EP Lab | January 29, 2026

Corify Care to Introduce First Whole-Heart Mapping Technology

The mapping technology delivers a global view of cardiac arrhythmias in a single beat

Corify Care to Introduce First Whole-Heart Mapping Technology

Jan. 28, 2026 — Corify Care has announced a major development in cardiac electrophysiology with the publication of its proprietary Global Volumetric Mapping technology in Nature Communications Medicine. The publication marks the first system capable of mapping all four heart chambers at once, providing physicians with a complete, real-time view of arrhythmias that current solutions cannot deliver.

Today’s mapping systems analyze the heart one chamber at a time, forcing clinicians to infer what they cannot see. Corify Care’s technology changes that paradigm. This evolution of this system, which mapped the heart’s surface, now allows visualization inside the cardiac walls and the septum. Its technology delivers a single-beat, whole-heart map, revealing how arrhythmias move through the heart wall and across chambers — before and during ablation.

“This is about visibility and confidence,” said Andreu Climent, PhD, CEO of Corify Care. “We give physicians the full picture upfront, not fragments. A global view means faster decisions, more targeted ablations, and the potential to reduce procedure time and complexity, providing clinical clarity”

Corify Care’s system uncovers arrhythmia pathways that are often missed with conventional tools, including circuits located deep within the heart wall or spanning multiple chambers. By eliminating blind spots, the platform helps physicians address complex cases with greater efficiency and predictability.

“For the first time, we can non-invasively see the heart as it truly behaves — globally,” said Felipe Atienza, MD, PhD, chief medical officer. “This has meaningful implications for workflow, outcomes, and scalability in EP labs.”

Jorge Vicente-Puig, PhD, lead author, added: “Our research demonstrates that a volumetric approach is essential for true arrhythmia characterization. We have moved beyond the mathematical limitations of the past to offer a complete 3D physiological picture.”

The ACORYS system is CE Marked and is currently under FDA review to meet regulatory requirements for the U.S. market.

Corify Care is actively advancing integrations with leading catheter navigation platforms to enable a seamless hybrid workflow, while developing several research lines, such as volumetric analysis. Data on Atrial Fibrillation and Ventricular Tachycardia will be presented at the AF Symposium 2026 in Boston in February.


Related Content

Feature | Heart Failure | Kyle Hardner

The shift toward steering appropriate cardiovascular cases to outpatient settings is gaining momentum, driven by a ...

Home September 11, 2026
Home
News | Heart Failure

Sept. 9, 2026— Atman Health has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to develop an ...

Home September 11, 2026
Home
News | Heart Failure

Aug. 31, 2026 — A new heart failure (HF) treatment effect calculator could help overcome one of the largest barriers to ...

Home August 31, 2026
Home
News | Heart Failure

July 28, 2026 — Abbott has initiated the Treat TR study, a post-market study of the company’s TriClip transcatheter edge ...

Home July 29, 2026
Home
News | Heart Failure

July 22, 2026 — Ultromics has announced results from an independent clinical data set that shows the company’s EchoGo ...

Home July 22, 2026
Home
News | Heart Failure

June 29, 2026 — A new international expert consensus document refines and updates how heart failure is identified and ...

Home June 30, 2026
Home
News | Heart Failure

May 28, 2026 — Coredio has announced that the U.S. Food and Drug Administration (FDA) has granted its Cardiac ...

Home May 28, 2026
Home
News | Heart Failure

May 10, 2026 — WhiteSwell has announced primary results from the DELTA-HF feasibility clinical trial evaluating the eLym ...

Home May 21, 2026
Home
Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Subscribe Now